-
That Monsanto, one of the most significant contributors to this research, has placed conditions on the use of its intellectual property or charges for access to its property is neither extraordinary nor problematic: Licensing agreements are complicated affairs, running into the dozens of pages, and they always preserve a range of protections for the patent holder.
FORBES: The Seeds Of An Antitrust Disaster In Iowa
-
Some generics firms are now agreeing to delay their launches not for cash but for a promise from the patent-holder to delay or cancel the launch of its authorised generic.
ECONOMIST: Generic drugs and competition
-
If EchoStar prevails, similarly-situated companies will have even less incentive to seek out deals with patent-holders, instead relying on the courts to carve out for them an extended period of unlicensed use with a bill that comes due years later assuming the patent holder can afford to litigate for years and in an amount almost certainly far below the actual benefit conferred.
FORBES: TiVo V. EchoStar: Abusing The Courts Instead Of Respecting The Patent